Takeda Pharmaceutical Company
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Values in USD · ADR · Reports in JPY
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
Current Price
$16.68
+0.60%GoodMoat Value
$44.87
169.0% undervaluedProfile
Valuation (TTM)
Market Cap$52.11B
P/E73.27
EV—
P/B1.12
Shares Out3.12B
P/Sales1.75
Revenue$29.80B
EV/EBITDA9.47
Takeda Pharmaceutical Company (TAK) Stock Analysis
Market Cap$52.11B
Current Price$16.68
P/E Ratio73.27
Forward P/E—
PEG Ratio0.21
EPS$0.23
Book Value$14.87
P/B Ratio1.12
TAK Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 0.9% FCF growth (CAGR)
Cash vs Debt
Net Debt: 31.3B
Revenue
30.5B
FY20
29.4B
FY21
29.3B
FY22
30.4B
FY23
28.2B
FY24
30.7B
FY25
28.2B
FY26
Net Income
410M
FY20
3.5B
FY21
1.9B
FY22
2.4B
FY23
952M
FY24
723M
FY25
1.2B
FY26
TAK 52-Week Range
$13.23
$18.80
50-Day MA: $17.44200-Day MA: $15.86
Did you know?
Trading 169% below its estimated fair value of $44.87.
Takeda Pharmaceutical Company (TAK) Financial Summary
Takeda Pharmaceutical Company (TAK) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NYSE. The stock currently trades at $16.68 with a market capitalization of $52.11B.
Key valuation metrics include a P/E ratio of 73.27, price-to-book ratio of 1.12, and EPS of $0.23. The company reports a profit margin of 2.5% and return on equity of 1.6%.
TAK Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $52.11B |
| P/E Ratio | 73.27 |
| EPS | $0.23 |
| P/B Ratio | 1.12 |
| P/S Ratio | 1.75 |
| EV/EBITDA | 9.47 |
| Dividend Yield | 3.89% |
| Profit Margin | 2.5% |
| Return on Equity | 1.6% |
| Debt/Equity | 0.76 |
TAK Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY20 | $30.50B | $410.02M |
| FY21 | $29.36B | $3.45B |
| FY22 | $29.28B | $1.89B |
| FY23 | $30.42B | $2.39B |
| FY24 | $28.16B | $951.57M |
| FY25 | $30.69B | $722.89M |
| FY26 | $28.21B | $1.20B |
Takeda Pharmaceutical Company (TAK) Valuation
Based on GoodMoat's DCF model, Takeda Pharmaceutical Company has a fair value estimate of $44.87. At the current price of $16.68, the stock appears 62.8% undervalued relative to our intrinsic value estimate.
TAK Quality Indicators
Takeda Pharmaceutical Company maintains a profit margin of 2.5% and an operating margin of 7.5%. Return on equity stands at 1.6%. The current ratio is 1.01. Debt-to-equity ratio is 0.76.
About Takeda Pharmaceutical Company
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
TAK Free Cash Flow
Takeda Pharmaceutical Company generated $5.52B in trailing twelve-month free cash flow, representing an FCF yield of 10.60%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
TAK Shares Outstanding
Takeda Pharmaceutical Company has 3.12 billion shares outstanding at a share price of $16.68, giving it a market capitalization of $52.11B.